Review Article

Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite

Tommaso C. Bulfone,1,2,3 Stephen P. Samuel,1,4 Philip E. Bickler,3 and Matthew R. Lewin1,2

1California Academy of Sciences, San Francisco, 94118 CA, USA
2Ophirex, Inc., Corte Madera, 94925 CA, USA
3University of California, San Francisco, 94118 CA, USA
4General Medicine, Queen Elizabeth Hospital, King’s Lynn, PE30 4ET, Norfolk, UK

Correspondence should be addressed to Tommaso C. Bulfone; tommaso.bulfone@gmail.com

Received 5 May 2018; Accepted 3 July 2018; Published 30 July 2018

Academic Editor: Marcel Tanner

Copyright © 2018 Tommaso C. Bulfone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The World Health Organization (WHO) recently added snakebite envenoming to the priority list of Neglected Tropical Diseases (NTD). It is thought that ∼75% of mortality following snakebite occurs outside the hospital setting, making the temporal gap between a bite and antivenom administration a major therapeutic challenge. Small molecule therapeutics (SMTs) have been proposed as potential prereferral treatments for snakebite to help address this gap. Herein, we discuss the characteristics, potential uses, and development of SMTs as potential treatments for snakebite envenomation. We focus on SMTs that are secretory phospholipase A2 (sPLA2) inhibitors with brief exploration of other potential drug targets on venom molecules.

1. Introduction

Snakebite envenomation is a neglected tropical disease that causes more than 100,000 deaths every year [1, 2]. Of the snakebites that are ultimately fatal, it is estimated that about 50-75% occur before victims can reach the hospital for antivenom treatment [3–6]. There is an urgent need for novel interventions to address the therapeutic and temporal gap between a bite and hospital-level care. Small molecule therapeutics (SMTs) have been proposed for initiating the treatment of snakebite in the prehospital environment and as adjuncts to antivenom therapy [7, 8].

2. Small Molecule Therapeutics

SMTs represent a potentially useful adjunctive therapy to antivenoms, the current mainstay of care for symptomatic snakebite. As a group, most SMTs are naturally occurring (e.g., alkaloid) or synthetic molecules that are usually intended to act on specific targets. G-protein coupled receptor systems comprise the largest group of targets for SMTs [9, 10]. SMTs could be used in multiple ways to decrease morbidity and mortality caused by snake envenomation (Figure 1). Ideally, an SMT could be given orally in the prereferral setting to diminish or delay venom toxicity. An SMT could also be used in an in-patient setting, either orally or intravenously, as an adjunct to antivenom and to increase the breadth of treatment efficacy. These uses could potentially reduce the required dosage of antivenom and improve treatment costs by improving the performance of imperfectly matched antivenoms. Finally, an SMT could be administered posthospitalization to reduce the chances of rebound effects from venom components not effectively or durably covered by antivenom. With low toxicity and high efficacy, SMTs could even be considered for prophylactic use in high-envenomation risk situations.

The search for nonserotherapy antidotes to snakebite is not new. Traditional healers have long used poultices and teas...
SMTs have many characteristics that make them potentially useful as an adjunctive therapy for snakebite treatment. If proven effective, SMTs might address some of the most significant limitations of antivenom (Figure 2) [21]. By their nature, SMTs are at low risk for allergenicity or anaphylactic shock as compared to most serum-based therapies [22]. In addition, many snake venoms have in common active toxic components that could be targeted by SMTs, including the secreted phospholipase A2 (sPLA₂) and metallo- and serine-proteases (svMPs and SPs, respectively). If the inhibitory targets are common among snake species, SMTs could potentially have broad spectrum "venom agnostic" effects. This would potentially decrease the importance of snake identification and would increase the usefulness of SMTs as first-line therapeutics. Venom agnostic SMTs could be used in a broad range of geographical areas and potentially eliminate the need of an expert to confirm snake species prior to initializing treatment, though newly developed rapid diagnostics could rapidly refine the specificity of treatment and improve the clarity and powering of clinical studies where more than one type of venomous snake is prevalent [23, 24]. Finally, in theory, multiple SMTs developed against various venom proteins could be combined to inhibit wider varieties of toxins present across snake species.

For SMTs to be potentially useful as an adjunctive therapy for snakebite, they should be heat stable and easily administered, allowing point-of-care treatments in the field. Also, the manufacturing cost-of-goods (COGS) of SMT should be comparatively low. Consideration of repositioned (repurposed) compounds with a history of use in humans, a strategy discussed in detail below, could further decrease costs of development [8, 25]. Also, venom distributes outside...
the blood, with an average volume of distribution in animals of 0.054-0.070 L/Kg, where antivenom cannot distribute [26]. Given their small molecular weight and charge, SMTs will generally have much higher volumes of distribution and tissue penetration than antivenom, allowing them to distribute within vulnerable tissues [26–30]. The addition of tissue penetrating molecules could expand the time during which severe neurotoxicity could be reversed. This would be an advance in the field because of antivenom’s limited access to synaptic junctions and inability to reverse critical impairments such as respiratory paralysis.

WHO has provided a detailed preclinical assessment for antivenom development for snakebite treatment and has recently been reviewed in detail by Gutierrez et al. [31, 32]. However, none exists for SMT development for snakebite. Based on the WHO guidelines, previous studies on antivenom development, and our experience in the development of SMTs, the preclinical assessment of SMTs for snakebite treatment can be envisioned (Table 1).

### 3. Pathway for Development of an SMT

#### 3.1. Venom Target Selection

A toxin-centric approach might be the basis of next-generation snakebite treatment [33]. As described by Laustsen, snake venom is likely to be the “most complex pharmaceutical target” known, composed of a multitude of toxin components and complex biochemical interactions [34]. Thus, venom targets for inhibition should be, ideally, abundant across as many of the medically important snake species as possible. For understanding venom properties and targeting, proteomic analysis of snake venom has been crucial to reveal species variation in venom composition and toxicity [35–37]. Proteomic analysis has revealed a wide array of active toxic ingredients from at least 26 protein families, but the most common medically relevant components are found within four families in varying proportions [38–40]. These proteins are secreted phospholipase A2 (sPLA$_2$), metallo- and serine-proteases (svMP and SP), and the nonenzymatic three-finger toxins (3-FTX).

#### Table 2: Generic pathogenesis of major toxins in snake venom: secreted phospholipase A2 (sPLA$_2$), metallo- and serine-proteases (svMP and SP), and the nonenzymatic three-finger toxins (3-FTX).

<table>
<thead>
<tr>
<th>Family</th>
<th>sPLA$_2$</th>
<th>svMP</th>
<th>SP</th>
<th>3-FTX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurotoxic</td>
<td>Yes</td>
<td>-</td>
<td>-</td>
<td>Yes</td>
</tr>
<tr>
<td>Hemotoxic</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>-</td>
</tr>
<tr>
<td>Myotoxic</td>
<td>Yes</td>
<td>Yes</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cytotoxic</td>
<td>Yes</td>
<td>Yes</td>
<td>-</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Because of its ubiquity and clinically significant effects, we focus on sPLA$_2$ as a candidate for inhibition by SMTs [31, 40]. Snake venom sPLA$_2$ play roles in early- and late-onset symptomology, as well as synergistic and regulatory roles for other coexisting snake venom components [45–52]. sPLA$_2$ are also some of the most pharmacologically active, multieffect (neuro-myco-cyto-hemotoxic) venom components (Table 2) [45–53].
svMPs represent another important target for inhibition because of their systemic and local toxicity, caused by fibrinolytic and hemorrhagic activity among others [1, 49]. Recent studies suggest that small molecules, in particular anticancer metalloprotease inhibitors and, possibly, metal chelators related to EDTA, have inhibitory effects on svMPs [18, 54–57]. SP inhibitors will be amongst the most challenging to develop because of their complex role in coagulation and short half-life of molecules that have made it to clinical use thus far, such as gabexate [58]. The most active work in this area has come from Vaiyapuri [59, 60]. 3-FTX toxin lacks enzymatic activity and presents a challenging target for an SMT. In addition, there is potential for single toxin inhibitors to affect synergistic effects of toxins, for example, sPLA2 potentiation of svMP in Bothrops alternatus venom [34, 61].

While sPLA2 inhibition might prove sufficient as a “bridge-to-survival” for many types of venoms when administered in a prereferral setting and, at times, be sufficient for treatment, future SMTs might be mixtures of other SMTs (Figure 3(a)). Some targets could also be inhibited indirectly by SMTs, such as 3-FTX, whose effects might sometimes be mitigated by acetylcholinesterase inhibitors, though the use of these inhibitors remains controversial despite decades of use for this purpose [41, 50, 62–64]. In addition, SMTs might be used to slow the spread of venom by paralyzing lymphatic smooth muscles (e.g., with lidocaine) [65]. SMTs could also be paired with antibodies or other biologicals to increase the range of efficacy or extend their paraspecificity (Figure 3(b)).

3.3. Repurposing as a Strategy for Discovery and Development.

To achieve a lower-cost SMT product that can be commercialized and priced sustainably, its development costs need to be lowered. The development of a new drug from lead discovery to launch can take many years and cost more than one billion USD [66]. Repurposing, a strategy for accelerated drug development by reviving or expanding indications of existing drugs, might be beneficial to the development of a potential SMT for snakebite. Repurposing, or repositioning, is a powerful way to reduce the cost of drug development, particularly for neglected tropical diseases that do not offer sufficiently alluring markets to larger pharmaceutical companies, such as snakebite [25, 67]. Repurposing compounds already in development can accelerate entry to clinical trials and result in significant savings. Repurposing can also revive the potential of drugs that never reached commercialization or expand the purpose of existing drugs by applying them to new indications [68]. Examples of successfully repurposed drugs include Thalomid (Thalidomide) for treatment of leprosy and Viagra (Sildenafil) for pulmonary hypertension [25, 68]. In 1972, Banerjee et al. presented an early example of repurposing an SMT for snakebite when neostigmine was used to treat the paralytic effects of an elapid bite [41].
Strategies for SMT Discovery
- High Throughput Screening
- Computer Modeling
- Fragment Optimization
- DNA Tag Library
- Hypothesis Testing
- Focused Screen for Repurposing

High Throughput Screening
- Compound Library
- Snake Venom 1
  - PLA2
  - svMP
  - SP
- Snake Venom 2
  - PLA2
  - svMP
  - SP
- Primary Screening
- Confirmation of Hits

Target Selection → Lead Discovery → Pre-Clinical Development → Clinical Development → Approval

4. Repurposed Drugs and Model SMT Candidates for Enzymatic Inhibition of Snake Venom

We recently identified a previously studied sPLA₂ inhibitor, varespladib (syn. LY315920, S-920), and its orally bioavailable prodrug, methyl-varespladib (syn. LY333013, A-002), as a candidate treatment for snake envenomation [8]. Varespladib appears to be a potent sPLA₂ inhibitor against a broad spectrum of snake venom sPLA₂s. As mentioned above, the ubiquity and clinically significant effects of snake venom sPLA₂s across venom types make it a plausible candidate for inhibition by an SMT with potential for broad spectrum of efficacy.

Varespladib, for the indication snakebite, is an example of a potentially repurposed compound. In recent decades, several large pharmaceutical industry endeavors focused on sPLA₂ inhibition for potential anti-inflammatory and cardiovascular drugs but, to date, none came to market [70, 71].

Multiple groups have since investigated the use of this class of acetylcholinesterase inhibitors in the clinical or laboratory setting with variable results [41, 50, 63, 64]. Development of a hypothetical SMT using a repurposing pathway is shown in Figure 5.

Drug repurposing does not generally require further optimization or structural modification of an FDA-approved drug or lead compound, unless formulations were altered from original studies, which may require extra characterization and testing [25]. Therefore, data from efficacy, safety, pharmacokinetics/dynamics studies, and others conducted for the initial indication of the compound can be reused for the new indication if the originators donate, license, or sell access to their data [69]. In regards to safety, Klug et al. note that “the most common side effects of the repurposed drugs are minor in comparison to those of many existing NTD therapeutics” [25]. Repurposing can be a cost-effective, lower-risk strategy to rapidly develop new SMTs for snakebite treatment.
sPLA$_2$ enzymes are present throughout the animal kingdom and are involved in multiple key processes, such as synaptic transmission and inflammation. sPLA$_2$ are implicated as having roles in various important diseases such as sepsis, cardiovascular disease, neurological disease, rheumatological disease, and cancer [72]. In attempts to treat these diseases, several companies devoted extensive resources to developing sPLA$_2$ inhibitors as targets for drug development. These inhibitors could be considered for repurposing as SMTs for snakebite treatment.

Figure 6 shows the structures of the sPLA$_2$ inhibitor, varespladib, and other SMT candidates that could be repurposed, the anti-svMP peptidomimetic SMTs, prinomastat, and marimastat [17, 18, 54]. Varespladib is a sPLA$_2$ inhibitor originally developed by Shionogi and Lilly, for treatment of pancreatitis and sepsis and, later, licensed to Anthera, for treatment of acute chest syndrome and heart disease [73, 74]. This makes it an inviting candidate for repurposing because of the known safety profile and, thus, potentially reduced development costs [8, 75, 76]. Similarly, MP inhibitors that have previously been developed for cancer treatment such as batimastat, marimastat, and prinomastat could also be considered [11, 12, 77, 78].

In vitro, varespladib was observed to be a surprisingly potent inhibitor of snake venom sPLA$_2$. The observed consistent potency (nano- and subnanomolar range) against a range of sPLA$_2$ from more than 25 medically important snakes from six continents suggest that these could be scaled for human use at reasonable dose volumes and dosage forms [8]. In vivo, rescue studies using lethal doses of coral snake (M. fulvius) and common adder (V. berus) venom were performed on mice to whom venom was administered subcutaneously followed by intravenous varespladib in the lateral tail vein, and all survived for at least 24 h, while those receiving only venom died in a matter of minutes or hours. Similarly, mice subjected to intraperitoneal administration of venoms were rescued by intravenous, intramuscular, and oral routes of drug administration against venoms from snakes such as D. russell, E. carinatus sochureki, O. scutellatus, C. scutulatus, and C. durissus terrificus (unpublished data). In addition, recent results by Wang et al. (2018) showed the inhibitory effect of varespladib treatment on D. acutus, A. halys, N. atra, and B. multicinctus in vitro and in vivo [79]. The results of these experiments have led to several new questions, including the exact mechanism by which survival is enhanced by these experimental drugs.

For a repurposed compound, attention should be given to the safety signals seen in prior trials. Consideration of the difference in use of an SMT between previous indication and snakebite might mitigate safety risks: for example, an SMT for snakebite would be used acutely, with one or few doses, rather than chronically. If use of SMTs includes early administration in the field, potentially before appearance of signs of envenomation, safety of the drug for individuals bitten by nonvenomous snakes or individuals exposed to “dry” bites must be considered. In terms of efficacy, the risk that inhibition of one toxin (e.g., sPLA$_2$ or svMP) might not be sufficient and can be mitigated by addressing additional targets and having backup molecules potentially more suitable for different geographic regions [54]. Lastly, means for commercialization should be evaluated early on to determine real world feasibility of implementing an SMT.
5. Conclusions

SMTs are potentially useful tools and could meet key development criteria as initial field treatment for snakebite and as adjuncts to antivenom with unrealized potential.

The rational development of an SMT commences with selecting an inhibitory target and determination of the breadth of efficacy across snake species. The breadth of effect helps determine the applicability to specific geographical regions and snake types. Aiding the discovery step is the availability of SMTs already developed by the pharmaceutical industry for other indications, which, if repurposed, could substantially lower development costs and increase the potential for accelerated approvals. Preclinical studies to evaluate the safety and efficacy of the SMT follow similar assays used in antivenom testing, but other assays to test heat stability, ease of administration, and bioavailability are likely to be additionally performed. A careful, systematic, and multidisciplinary approach will be required to determine the most appropriate next steps in the development and deployment of new therapeutic classes for the initial treatment and overall management of snakebite.

Conflicts of Interest

Matthew R. Lewin is associated with intellectual property related to the commercial development of varespladib and Tommaso C. Bullone, Philip E. Bickler, and Stephen P. Samuel have been consulted.

Authors’ Contributions

All authors contributed equally to the production of this manuscript.

References


[38] “Relative Abundance Display Tropical Pharmacology Lab Available online,” https://tropicalpharmacology.com/venomics-display/relative-abundance-display/.


[58] M. Yuksel, “Gabexate Mesilate, a Synthetic Protease Inhibitor, Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-Alpha Production by Inhibiting Activation of Both Nuclear Factor-kappa B and Activator Protein-1 in Human Monocytes,”


